Savient Shifts Focus To Puricase Submission For Refractory Gout
This article was originally published in The Pink Sheet Daily
The firm restructures its commercial operations and terminates 19-rep sales force detailing its anabolic agent Oxandrin.
You may also be interested in...
Launch follows denial of Savient’s motion for preliminary injunction to prevent Sandoz and Upsher-Smith from launching generic oral anabolic agent.
Febuxostat would be the first new treatment for chronic gout in more than 40 years.
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.